GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in an upcoming investor conference.
Senseonics’ management is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, New York, on Wednesday, February 14, 2018 at 1:00pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical
technology company focused on the design, development and
commercialization of glucose monitoring products designed to help people
with diabetes confidently live their lives with ease. Senseonics’ first
generation CGM system, Eversense, includes a small sensor, smart
transmitter and mobile application. Based on fluorescence sensing
technology, the sensor is designed to be inserted subcutaneously and
communicate with the smart transmitter to wirelessly transmit glucose
levels to a mobile device. After insertion, the sensor is designed to
continually and accurately measure glucose levels.
